# Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor

> **NCT02842333** · NA · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 57 (actual)

## Conditions studied

- Chronic Leukemia

## Interventions

- **OTHER:** Additional biological samples

## Key facts

- **NCT ID:** NCT02842333
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-10-06
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842333, "Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02842333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*